Inoviem Scientific is a privately owned Contract Research Biotech (CRB) company that specializes in preclinical and clinical services aimed at improving the drug development process. The company leverages cutting-edge proprietary technologies to enhance lead compound selection and decrease attrition rates by better predicting drug effects and safety. Inoviem serves a diverse range of clients, including both public and private organizations involved in the discovery and development of innovative drugs. Operating in the pharmaceutical and biotech sectors, Inoviem's business model revolves around offering specialized research services that accelerate drug development timelines and improve success rates. The company generates revenue through service contracts with pharmaceutical companies and other research institutions.

Keywords: Contract Research Biotech, drug development, lead compound selection, attrition rates, proprietary technologies, preclinical services, clinical services, pharmaceutical clients, biotech sector, research services.